In particular, a drug called Evusheld could offer protection for people who are vulnerable – but the UK isn’t offering it.
Evusheld is an antibody drug from AstraZeneca intended to help prevent COVID-19 infection for immunocompromised and other vulnerable patients.
The pandemic lifestyle we are all adjusting to is the life families of children with cancer have already been living. But there have been positives, too.
As we continue to roll out COVID-19 vaccines around the world, we’re learning people who are immunocompromised aren’t necessarily protected as well from the first two doses.
People with weakened immune systems are at a high risk of severe and prolonged COVID-19 infections. An extra vaccine dose can bolster protection.
Being immunocompromised appears to affect the vaccine response, but this seems to vary depending on the causes of the person’s low immunity.
A discussion is long overdue on how immune-insecure people have to deal with COVID-19.
Though currently approved COVID-19 vaccines effectively provide immunity against the virus, it’s unclear how long that protection will last.
Prevention may be the best way to cope with the worldwide wave of treatment-resistant fungal pathogens.
For people who are immunodeficient, the usual controls of the immune system don’t work as well. This can affect how they respond to vaccines. But this group should still get the COVID jab.
Who is most likely to survive an infection of the new coronavirus? Two immunologists explain that it is those who mount exactly the right immune response – not too weak, not too strong.
Some people’s immune systems aren’t able to stop foreign invaders, such as COVID-19, as well as the rest of the population. There are many reasons for this, including illness, medications and age.
Success during the pandemic hinges on people taking social distancing seriously. What do you do when someone doesn’t? The people who negotiate humanitarian aid in crises have some lessons for you.